Revance Therapeutics, Inc. RVNC

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
45/100
Developing

Ranked against 712 peers in Biotechnology

Key strengths

  • Consistent Cash Generation Cash generation is strong and consistent (score 0.72).
  • Cash Generation Consistent Cash generation is consistent (score 0.72), indicating reliable business model.

Key risks

  • Commodity Pressure / Weak Differentiation Gross margin at 22.2th percentile with high volatility suggests weak pricing power or commoditized products.
  • ROIC Below WACC or Peers ROIC at 0th percentile suggests inefficient capital deployment.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Weak
20
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Where RVNC ranks in Biotechnology

Revance Therapeutics, Inc. ranks #296 of 713 scored companies in Biotechnology by moat score — the top 42%. The widest moat in the group is Royalty Pharma plc (RPRX) at 85/100.

# Company Moat score Rating
292 Amylyx Pharmaceuticals, Inc. AMLX 46/100 Developing
293 Kura Oncology, Inc. KURA 46/100 Developing
294 Vivani Medical, Inc. VANI 45/100 Developing
295 Relay Therapeutics, Inc. RLAY 45/100 Developing
296 Revance Therapeutics, Inc. RVNC 45/100 Developing
297 Autolus Therapeutics plc AUTL 45/100 Developing
298 Kyverna Therapeutics, Inc. KYTX 45/100 Developing
299 Vir Biotechnology, Inc. VIR 45/100 Developing
300 Sagimet Biosciences Inc. - Seri SGMT 45/100 Developing

See every Biotech / Pre-Revenue company ranked by moat score →

How RVNC scores on the Corporate Default defenses

Pricing Power

Score 20 · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Score 69 · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Score 47 · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 17 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 61 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Score 65 · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding RVNC's moat

What is Revance Therapeutics, Inc.'s moat score?

Revance Therapeutics, Inc. (RVNC) scores 45 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #296 of 713 scored companies in Biotechnology, the top 42%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Cost Advantage (69/100) and its weakest is Capital Efficiency (17/100).

How does Revance Therapeutics, Inc. compare with other Biotechnology companies?

Revance Therapeutics, Inc. ranks #296 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are Relay Therapeutics, Inc. (RLAY) at 45 just above it and Autolus Therapeutics plc (AUTL) at 45 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.

Why is Revance Therapeutics, Inc. scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for Revance Therapeutics, Inc.?

The Corporate Default template measures 6 defenses, and RVNC scores: Pricing Power (20), Cost Advantage (69), Customer Stickiness (47), Capital Efficiency (17), Resilience (61), Scale & Market Position (65). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000